WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently appointed Glenn Tyson as its first chief commercial officer as the company prepares for anticipated regulatory milestones tied to its ketamine-based treatments.
The appointment comes as NRx awaits approval of an Abbreviated New Drug Application for a preservative-free ketamine product and plans a near-term New Drug Application submission to expand ketamine labeling to include treatment for depression and suicidality.
Tyson brings clinical and commercial experience in mental health, including 25 years in pharmaceutical sales and product development. He began his career as a counselor working with patients with psychiatric conditions and addiction before moving into industry roles.
He spent 14 years at GlaxoSmithKline in senior commercial positions, followed by leadership roles at Indivior, where he served as vice president of strategy and new product development, senior vice president of sales and marketing, and later president of behavioral health. During his tenure, he led the launch of SUBLOCADE, a treatment for opioid addiction, which the company said delivered sustained quarterly growth.
More recently, Tyson has worked with companies developing neuroplastic therapies, including Transcend Therapeutics, which reported a $700 million agreement with Otsuka.
NRx said Tyson will oversee market access, distribution, sales, and marketing as the company prepares to commercialize its pipeline of psychiatric treatments.
In addition to its pending ANDA, NRx is preparing a New Drug Application under Fast Track designation for NRX-100, an intravenous ketamine formulation intended to treat severe depression in patients with suicidal ideation. The company is also advancing NRX-101, an oral combination therapy previously granted Breakthrough Therapy designation, designed to enhance the effectiveness of transcranial magnetic stimulation in treating depression and suicidality.
“We are excited for Glenn to join the NRx executive team,” said CEO and Chairman Dr. Jonathan C. Javitt. “His passion for people suffering with serious mental illnesses, and his experience building and leading commercial functions, gives us confidence as we prepare for anticipated product launches.”
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies targeting central nervous system disorders, including suicidal depression, chronic pain, and post-traumatic stress disorder.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.